Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targeting the CD4 molecule, effectively inhibiting T-cell receptor (TCR) signal transduction. It is used in research on rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

Zanolimumab, at concentrations of 10 and 100 ng/mL, effectively induces cytotoxicity in CD4+ T cells, demonstrating enhanced activity on the CD45RO+ subset compared to the CD45RA+ subset. Additionally, within a range of 1-10,000 ng/mL, the compound dose-dependently and through its Fc region, decreases CD4 expression on both purified primary CD4+ T cells and SUP-T1 T cells. Furthermore, Zanolimumab potently suppresses T-cell proliferation initiated by T-cell receptor (TCR) stimulation, as observed with both tetanus toxin and anti-CD3 challenges, and inhibits TCR signal transduction within a 0-30 minute timeframe.